
-
Summit Therapeutics NasdaqGM:SMMT Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.
Location: 601 Brickell Key Drive, Miami, FL, 33131, United States | Website: https://www.smmttx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
19.11B
Cash
361.3M
Avg Qtr Burn
-43.29M
Short % of Float
22.16%
Insider Ownership
84.31%
Institutional Own.
13.54%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ivonescimab + chemotherapy Details EGFR-mutated, advanced non-squamous NSCLC | BLA Submission | |
Ivonescimab (SMT112) Details 1L Non-small cell lung carcinoma | BLA Submission | |
Ivonescimab + chemotherapy Details EGFR-mutated, advanced non-squamous NSCLC | BLA Submission | |
Ivonescimab Details 1L PD-L1 positive Non-small cell lung carcinoma | Phase 3 Data readout | |
Ivonescimab Details PD-L1 positive NSCLC | Phase 3 Update | |
Ivonescimab (SMT112) +Chemotherapy Details Biliary Tract Cancer | Phase 2 Update | |
Ridinilazole Details Intestinal infection, Bacterial infection | Failed Discontinued |